TTR and polyneuropathy: On the other hand, inotersen has been approved by the FDA and Health Canada to treat patients with ATTR who have a mixed phenotype; however, its clinical trial, NEURO-TTR, showed that patients treated with this silencer tend to show improvements in their signs and symptoms of polyneuropathy [21].